FMC aims for 110,000 U.S. patients to be on Mircera in first-quarter
FRANKFURT (Reuters) - Kidney dialysis provider Fresenius Medical Care (FMC) expects more than 70 percent of eligible U.S. patients to have switched to cheaper alternative anemia treatment Mircera by the end of March, the German group's chief executive said.
Aucun commentaire:
Enregistrer un commentaire